Simvastatin modulates angiotensin II signaling pathway by preventing Rac1-mediated upregulation of p27

Journal of the American Society of Nephrology

Volumn 15, Issue 7, 2004, Pages 1711-1720

  Zeng, Lixia ^a   Xu, Hanshi ^a   Chew, Teng Leong ^a   Chisholm, Rex ^a   Sadeghi, Mehran M ^b   Kanwar, Yashpal S ^a   Danesh, Farhad R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; CYCLIN DEPENDENT KINASE INHIBITOR; GERANYLGERANYL PYROPHOSPHATE; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROGEN PEROXIDE; ISOPRENOID; LIPID; MEVALONIC ACID; PROTEIN KINASE B; PROTEIN P27; RAC1 PROTEIN; SIMVASTATIN; STATINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL STIMULATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION;

EID: 3042672869     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000129839.91567.68     Document Type: Article

References (50)

1. Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation 101: 207-213, 2000
2. Vaughan CJ, Gotto AM, Basson CT: The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35: 1-10, 2000
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol level: The Long Term Intervention With Pravastatin in Ischemic Heart (LIPID) study group. N Engl J Med 339: 1349-1357, 1998
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389, 1994
5. Usui H, Shikata K, Matsuda M, Okada S, Ogawa D, Yamashita T, Hida K, Satoh M, Wada J, Makino H: HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 18: 265-272, 2003
6. Kim SI, Kim HJ, Han DC, Lee HB: Effect of lovastatin on small GTP binding proteins and on TGF-β1 and fibronectin expression. Kidney Int 58: S88-S92, 2000
7. Casey PJ: Protein lipidation in cell signaling. Science 268: 221-225, 1995
8. Goldstein JL, Brown MS: Regulation of mevalonate pathway. Nature 343: 425-430, 1990
9. Scita G, Tenca P, Frittoli E, Tocchetti A, Innocenti M, Giardina G, Di Fiore PP: Signaling from Ras to Rac and beyond: Not just a matter of GEFs. EMBO J 19: 2393-2398, 2000
10. Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Sahai A, Kanwar YS: 3-Hydroxy-3-methyglutarel CoA reductase inhibitors prevent high glucose induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci U S A 99: 8301-8305, 2002
11. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21: 1712-1719, 2001
12. Takai Y, Sasaki T, Matozaki T: Small GTP-binding proteins. Physiol Rev 81: 153-208, 2001
13. Ridley AJ, Hall A: The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70: 389-400, 1992
14. Ridley AJ, Paterson HF, Johnston CL, Dickmann D, Hall A: The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 70: 401-410, 1992
15. Post GR, Golstein D, Thuerauf J, Glembotski CC, Brown JH: Dissociation of p44 and p42 mitogen-activated protein kinase activation from receptor-induced hypertrophy in neonatal rat ventricular myocytes. J Biol Chem 271: 8452-8457, 1996
16. Gorin Y, Ricono JM, Kim NH, Bhandari B, Choudhury GG, Abboud HE: Nox4 mediates angiotensin II-induced activation of Akt/protein kinase B in mesangial cells. Am J Physiol Renal Physiol 285: F219-F229, 2003
17. Shankland SJ, Wolf G: Cell cycle regulatory proteins in renal disease: Role in hypertrophy, proliferation, and apoptosis. Am J Physiol Renal Physiol 278: F515-F529, 2000
18. Wolf G, Stahl RAK: Angiotensin II-stimulated hypertrophy of LLC-PKI cells depends on the induction of the cyclin dependent kinase inhibitor p27Kip1. Kidney Int 50: 2112-2119, 1996
19. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Longterm prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 97: 8015-8020, 2000
20. Leehey DJ, Singh AK, Alavi N, Singh R: Role of angiotensin II in diabetic nephropathy. Kidney Int 5: S93-S98, 2000
21. Anderson PW, Do YS, Hsueh WA: Angiotensin II causes mesangial cell hypertrophy. Hypertension 21: 29-35, 1993
22. Miller JA: Impact of hyperglycemia on the renin angiotensin system in early human type I diabetes. J Am Soc Nephrol 10: 1778-1785, 1999
23. Kip1. Kidney Int 50: 2112-2119, 1996
24. Kip1 in angiotensin II-stimulated vascular smooth muscle cell hypertrophy. J Clin Invest 104: 815-823, 1999
25. Kip1 in cultured mouse mesangial cells: Relationship to hypertrophy. Am J Physiol Renal Physiol 273: F348-F356, 1997
26. Kip1 an inhibitor of cyclin-dependent kinases. Am J Pathol 158: 1091-1100, 2001
27. Kip1 in diabetic db/db mouse: Role of hyperglycemia. Kidney Int 53: 869-879, 1998
28. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685, 1995
29. Hengst L, Reed SI: Translational control of p27Kip1 accumulation during the cell cycle. Science 271: 1861-1864, 1996
30. Fujita N, Sato S, Tsuruo T: Phosphorylation of p27Kip1 at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization. J Biol Chem 278: 49254-49260, 2003
31. Tomoda K, Kubota Y, Kato J: Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 398: 160-165, 1999
32. Muller D, Bouchard C, Rudolph B, Steiner P, Stuckmann I, Saffrich R, Ansorge W, Huttner W, Eilers M: Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes. Oncogene 15: 2561-2576, 1997
33. Kip1: Role in angiotensin ii-mediated hypertrophy of proximal tubular cells. J Am Soc Nephrol 11: 1387-1397, 2000
34. Thannickal VJ, Fanburg BL: Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 279: L1005-L1028, 2000
35. Ha H, Lee HB: Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. Kidney Int 77: S19-S25, 2000
36. Kamata H, Hirata H: Redox regulation of cellular signalling. Cell Signal 11: 1-14, 1999
37. Irani K: Oxidant signaling in vascular cell growth, death, and survival: A review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 87: 179-183, 2000
38. Downward J: Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10: 262-627, 1998
39. Igel M, Sudhop T, von Bergmann K: Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 57: 357-364, 2001
40. Evans M, Rees A: Effects of HMG-CoA reductase inhibitors on skeletal muscle: Are all statins the same? Drug Saf 25: 649-663, 2002
41. Blanco-Colio LM, Villa A, Ortego M, Hemandez-Presa MA, Pascual A, Plaza JJ, Egido J: 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 161: 17-26, 2002
42. Knapp AC, Huang J, Starling G, Kiener PA: Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis 152: 217-227, 2000
43. Weis M, Heeschen C, Glassford AJ, Cooke JP: Statins have biphasic effects on angiogenesis. Circulation 105: 739-745, 2002
44. Kip1 ameliorates progression of diabetic nephropathy. J Am Soc Nephrol 14: 699-708, 2003
45. Aikawa R, Komuro I, Nagai R, Yazaki Y: Rho plays an important role in angiotensin II-induced hypertrophic responses in cardiac myocytes. Mol Cell Biochem 212: 177-182, 2000
46. Natarajan R, Gerrity RG, Gu JL, Lanting L, Thomas L, Nadler JL: Role of 12-lipoxygenase and oxidant stress in hyperglycemia-induced acceleration of atherosclerosis in diabetic pig model. Diabetologia 45: 125-133, 2002
47. Jaimes EA, Galceran JM, Raij L: Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 54: 775-784, 1998
48. Gorin Y, Kim NH, Feliers D, Bhandari B, Choudhury GG, Abboud HE: Angiotensin II activates Akt/protein kinase B by an arachidonic acid/redox-dependent pathway and independent of phosphoinositide 3-kinase. FASEB J 15: 1909-1920, 2001
49. Hixon ML, Muro-Cacho C, Wagner MW, Obejero-Paz C, Millie E, Fujio Y, Kureishi Y, Hassold T, Walsh K, Gualberto A: Akt1/PKB upregulation leads to vascular smooth muscle cell hypertrophy and polyploidization. J Clin Invest 106: 1011-1020, 2000
50. Wolf G, Wenzel UO: Angiotensin II and cell cycle. Hypertension 43: 1-6, 2004